These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38709580)

  • 41. Newly diagnosed multiple myeloma.
    Weber DM
    Curr Treat Options Oncol; 2002 Jun; 3(3):235-45. PubMed ID: 12057069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple myeloma--presenting as acute kidney injury.
    Prakash J; Niwas SS; Parekh A; Vohra R; Wani IA; Sharma N; Usha
    J Assoc Physicians India; 2009 Jan; 57():23-6. PubMed ID: 19753754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.
    Freimann H; Calderoni A; Cornu P; Olie R
    Swiss Med Wkly; 2007 Jun; 137(21-22):317-22. PubMed ID: 17629810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
    Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The evolution and impact of therapy in multiple myeloma.
    Laubach JP; Richardson PG; Anderson KC
    Med Oncol; 2010 Jun; 27 Suppl 1():S1-6. PubMed ID: 20169425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple Myeloma: Diagnosis and Treatment.
    Michels TC; Petersen KE
    Am Fam Physician; 2017 Mar; 95(6):373-383. PubMed ID: 28318212
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
    Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N
    Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities.
    Paner A; Okwuosa TM; Richardson KJ; Libby EN
    Expert Rev Hematol; 2018 Dec; 11(12):957-973. PubMed ID: 30339769
    [No Abstract]   [Full Text] [Related]  

  • 52. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
    Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
    Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
    Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Balloon kyphoplasty: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2004; 4(12):1-45. PubMed ID: 23074451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current and emerging treatments for multiple myeloma.
    Schwartz RN; Vozniak M
    J Manag Care Pharm; 2008 Sep; 14(7 Suppl):12-9. PubMed ID: 18774881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bisphosphonates in multiple myeloma: an updated network meta-analysis.
    Mhaskar R; Kumar A; Miladinovic B; Djulbegovic B
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003188. PubMed ID: 29253322
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
    Rajkumar SV
    Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.